• 1
    Cancer Registry of Norway. Cancer in Norway 2010: Cancer Incidence, Mortality, Survival and Prevalence in Norway. Oslo: Cancer Registry of Norway; 2012.
  • 2
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.
  • 3
    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103104.
  • 4
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:1017.
  • 5
    Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8:261271.
  • 6
    Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13:e353e361.
  • 7
    Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155:770776.
  • 8
    Moberger B, Auer G, Forsslund G, Moberger G. The prognostic significance of DNA measurements in endometrial carcinoma. Cytometry 1984;5:430436.
  • 9
    Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS. 2002;110:673689.
  • 10
    Wik E, Trovik J, Iversen OE, Engelsen IB, Stefansson IM, Vestrheim LC, Haugland HK, Akslen LA, Salvesen HB. Deoxyribonucleic acid ploidy in endometrial carcinoma: A reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol. 2009;201:603e1603e7.
  • 11
    Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:8995.
  • 12
    Majewski IJ, Bernards R. Taming the dragon: Genomic biomarkers to individualize the treatment of cancer. Nat Med 2011;17:304312.
  • 13
    Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491505.
  • 14
    Williams BR, Amon A. Aneuploidy: cancer's fatal flaw? Cancer Res 2009;69:52895291.
  • 15
    Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining ‘chromosomal instability’. Trends Genet 2008;24:6469.
  • 16
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:5770.
  • 17
    Sieber OM, Heinimann K, Tomlinson IP. Genomic instability: The engine of tumorigenesis? Nat Rev Cancer 2003;3:701708.
  • 18
    Loeb LA. A mutator phenotype in cancer. Cancer Res 2001;61:323032339.
  • 19
    Kaern J, Wetteland J, Trope CG, Farrants GW, Juhng SW, Pettersen EO, Reith A, Danielsen HE. Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. Cytometry 1992;13:314321.
  • 20
    Haroske G, Baak JP, Danielsen H, Giroud F, Gschwendtner A, Oberholzer M, Reith A, Spieler P, Bocking A. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001;23:8995.
  • 21
    Darzynkiewicz Z, Halicka HD, Zhao H. Analysis of cellular DNA content by flow and laser scanning cytometry. Adv Exp Med Biol 2010;676:137147.
  • 22
    Rossi E, Ubiali A, Balzarini P, Cadei M, Alpi F, Grigolatoi PG. High-level detection of gene amplification and chromosome aneuploidy in extracted nuclei from paraffin-embedded tissue of human cancer using FISH: A new approach for retrospective studies. Eur J Histochem 2005;49:5358.
  • 23
    Massoner A, Augustin F, Duba HC, Zojer N, Fiegl M. FISH cytogenetics and prognosis in breast and non-small cell lung cancers. Cytometry B Clin Cytom 2004;62B:5256.
  • 24
    Muresu R, Sini MC, Cossu A, Tore S, Baldinu P, Manca A, Pisano M, Loddo C, Dessole S, et al. Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. Eur J Cancer 2002;38:18021809.
  • 25
    Jhala DN, Atkinson BF, Balsara GR, Hernandez E, Jhala NC. Role of DNA ploidy analysis in endometrial adenocarcinoma. Ann Diagn Pathol 2001;5:267273.
  • 26
    Lundgren C, Auer G, Frankendal B, Moberger B, Nilsson B, Nordstrom B. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002;12:110118.
  • 27
    Lundgren C, Frankendal B, Silfversward C, Nilsson B, Tryggvason K, Auer G, Nordstrom B. Laminin-5 gamma2-chain expression and DNA ploidy as predictors of prognosis in endometrial carcinoma. Med Oncol 2003;20:147156.
  • 28
    Mariani A, Sebo TJ, Webb MJ, Riehle D, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 2003;27:434441.
  • 29
    Orbo A, Rydningen M, Straume B, Lysne S. Significance of morphometric, DNA cytometric features, and other prognostic markers on survival of endometrial cancer patients in northern Norway. Int J Gynecol Cancer 2002;12:4956.
  • 30
    Suehiro Y, Okada T, Anno K, Okayama N, Ueno K, Hiura M, Nakamura M, Kondo T, Oga A, et al. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res. 2008;14:33543361.
  • 31
    Susini T, Amunni G, Molino C, Carriero C, Rapi S, Branconi F, Marchionni M, Taddei G, Scarselli G. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 2007;109:882890.
  • 32
    Baak JP, Snijders W, van Diermen B, van Diest PJ, Diepenhorst FW, Benraadt J. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol 2003;21:42144221.
  • 33
    Lundgren C, Auer G, Frankendal B, Nilsson B, Nordstrom B. Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol 2004;43:4956.
  • 34
    Santala M, Talvensaari-Mattila A. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma. Anticancer Res 2003;23:51915196.
  • 35
    Song T, Lee JW, Kim HJ, Kim MK, Choi CH, Kim TJ, Bae DS, Kim BG. Prognostic significance of DNA ploidy in stage I endometrial cancer. Gynecol Oncol. 2011;122:7982.
  • 36
    Terada K, Mattson D, Goo D, Shimizu D. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol 2004;95:483487.
  • 37
    Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Trope CG, Kristensen GB, Risberg BA. Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 2012;23:11781184.
  • 38
    Pradhan M, Davidson B, Abeler VM, Danielsen HE, Trope CG, Kristensen GB, Risberg BA. DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium. Virchows Arch 2012;461:291298.
  • 39
    Fredstorp-Lidebring M, Bendahl PO, Brunner N, Casslen B, Hogberg T, Langstrom-Einarsson E, Willen R, Ferno M. Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer 2001;37:23392348.
  • 40
    Mariani A, Sebo TJ, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000;182:15351544.
  • 41
    Steinbakk A, Malpica A, Slewa A, Skaland I, Gudlaugsson E, Janssen EA, Lovslett K, Fiane B, Kruse AJ, et al. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Mod Pathol 2011;24:12621271.
  • 42
    Pollack A, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, et al. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol 2003;21:12381248.
  • 43
    Bendardaf R, Lamlum H, Ristamaki R, Algars A, Collan Y, Pyrhonen S. Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content. Oncology 2004;66:4652.
  • 44
    Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS, Vandenput I, Amant F, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011;17:33683377.
  • 45
    Ormerod MG, Tribukait B, Giaretti W. Consensus report of the task force on standardisation of DNA flow cytometry in clinical pathology. DNA Flow Cytometry Task Force of the European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998;17:103110.
  • 46
    Strang P, Stenkvist B, Bergstrom R, Stendahl U, Valdes del Campo M, Tribukait B. Flow cytometry and interactive image cytometry in endometrial carcinoma. A comparative and prognostic study. Anticancer Res 1991;11:783788.
  • 47
    Darzynkiewicz Z. Critical aspects in analysis of cellular DNA content. Curr Protoc Cytom 2010;Chapter 7:Unit7.2.
  • 48
    Atkin NB. Frequency of hyperdiploid chromosome complements in endometrioid tumors of the endometrium whereas similar tumors in the ovary tend to show hypodiploidy: A significant difference that may not be distinguishable by flow cytometry of DNA content. Cytogenet Genome Res 2002;97:3942.
  • 49
    El-Naggar AK, Dinh M, Tucker SL, Swanson D, Steck K, Vielh P. Numerical chromosomal changes in DNA hypodiploid solid tumors: restricted loss and gain of certain chromosomes. Cytometry 1999;37:107112.
  • 50
    Ongoing clinical trial: Molecular Markers in Treatment en Endometrial Cancer (MoMaTEC) study, Clinicaltrialsgov Identifier: NCT00598845. Available at (Feb 2014).